New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
16:16 EDTMACK, SNYMerrimack to regain worldwide rights to commercialize MM-121
Merrimack Pharmaceuticals (MACK) announced that it has reached an agreement with Sanofi (SNY) to regain worldwide rights to develop and commercialize MM-121, a monoclonal antibody designed to block ErbB3, or HER3, activation in patients with heregulin-positive tumors and improve response to standard of care treatments. In partnership with Sanofi, Merrimack completed an extensive Phase 2 program for MM-121 which was designed to assess the role of ErbB3 in a number of cancer indications in both the metastatic and neoadjuvant settings. In advanced settings of ovarian cancer, ER/PR+ HER2 negative breast cancer and non-small cell lung cancer, Merrimack was able to identify that heregulin, the principal ligand that binds to and activates the ErbB3 receptor, is associated with poor response to standard of care therapy and that adding MM-121 may restore sensitivity in these most at-risk patients. Consistent across three metastatic cancer indications with three different standard of care therapies, patients in these trials with heregulin-positive tumors experienced a statistically significant reduction in their risk of progression when they received a combination with MM-121. Heregulin-driven drug resistance pathways were found to be active in approximately 30%-50% of patients tested.
News For MACK;SNY From The Last 14 Days
Check below for free stories on MACK;SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
13:58 EDTSNYRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
08:35 EDTSNYIntrexon enters into ECC with Sanofi subsidiary to develop APIs
Subscribe for More Information
07:21 EDTSNYRegeneron data positive, says RBC Capital
Subscribe for More Information
August 31, 2014
14:22 EDTSNYSanofi, Regeneron announce results from four Phase 3 ODYSSEY trials
Subscribe for More Information
12:50 EDTSNYEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
12:23 EDTSNYNovartis drug data to be presented this weekend
Subscribe for More Information
10:06 EDTSNYSanofi unit treatment of Fabry's disease granted orphan status
Subscribe for More Information
08:18 EDTSNYPerrigo among companies showing interest in Omega Pharma, Bloomberg says
Subscribe for More Information
August 25, 2014
12:19 EDTSNYOn The Fly: Midday Wrap
Subscribe for More Information
11:48 EDTSNYSanofi and Regeneron co-host a conference call
Subscribe for More Information
10:40 EDTSNYBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
August 22, 2014
12:39 EDTSNYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 21, 2014
05:42 EDTSNYIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 19, 2014
16:46 EDTSNYFDA approves Genzyme Cerdelga capsules
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use